Stock fact sheet · data as of
CorMedix Inc. (CRMD): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United States · High Growth
Is CRMD undervalued?
At 7.46 (close of 16 Oct 2026), CRMD trades 91% below the GLS average fair value of 83.15. That average comes from 7 models run on the latest filings, and 7 of them land above the current price. Margins of safety over 30% are the exception rather than the rule across the ~7,400 stocks we value each night, so the number earns CorMedix Inc. the full Value points in the Wheel Score - and a closer look at what the market is pricing in.
The 7 models disagree widely: Graham Number gives 17.76 while GLS Growth gives 146.07. A spread that wide means the average is sensitive to which methods you trust; the model table below shows where each one lands, and the Quote page lets you switch any of them off.
The nightly engine files CRMD under High Growth: revenue and earnings growing fast enough that the growth-based models carry the valuation.
Nine valuation models for CRMD
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | 17.76 | +138% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 136.48 | +1730% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 59.65 | +700% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 146.07 | +1858% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | 68.48 | +818% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | 127.06 | +1603% | Eight years of compounded free cash flow: the price at which the business pays for itself |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 26.51 | +255% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | -0.6900 | -109% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 14.50 | +94% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Financial health is weak: CRMD passes 4 of the nine Piotroski tests. Our screens drop the stock at the health rule; a low score is often the reason a stock looks cheap on the valuation models. The GLS Moat score is 5.5 out of 10: a ten-year record that is consistent in some of the metrics the score tracks (revenue, earnings, margins, cash flow, returns on capital) and patchy in others.
Returns on capital are high - ROIC 29.4%, ROE 40.2%, ROA 19.7% - with debt at 0.37 times equity and a free-cash-flow yield of 43.3%.
CorMedix Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Product 93%, Contract Revenue 5%, Grant Income 3% (quarter Q2 FY2026).
Institutional ownership scores 7/10, insider activity 3/10 and Congressional trading 5/10 on the GLS smart-money scales; the last recorded insider buy was on 18 Sep 2026.
| Piotroski F-score | 4 / 9 | ROIC | 29.4% |
|---|---|---|---|
| GLS Moat | 5.5 / 10 | ROE | 40.2% |
| Debt / equity | 0.37 | ROA | 19.7% |
| Free-cash-flow yield | 43.3% | Payout ratio | 0% |
| Institutions | 7 / 10 | Insiders · Congress | 3 · 5 / 10 |
Wheel Score 69: Good
CRMD scores 69 out of 100 on the Wheel Score (Good band, 65-79). The score blends the margin of safety (Value, 25/25), Piotroski health (9/20), the GLS moat (8/15), the option premium on offer (13/20) and how easily the stock trades (14/20). Health (9/20) is the part holding the score back.
Implied volatility is 88% on the near-the-money contracts 20-60 days out - above the 60% ceiling of the sweet spot. Premiums are large, but the Wheel Score tapers the Premium points (13 of 20) because volatility this high usually comes with a reason. Chain open interest is 33,735 contracts across all expiries - enough for the wheel at normal size.
Volume runs at 1.5M shares a day on a market cap of $581M, with a beta of 1.41 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 14 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 25 / 25 | 91% margin of safety | |
| Health | 9 / 20 | Piotroski 4/9 | |
| Moat | 8 / 15 | moat 5.5/10 | |
| Premium | 13 / 20 | implied volatility 88% | |
| Stability | 14 / 20 | 1.5M shares/day, $581M cap, beta 1.41 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 11 Nov 2026 (before the open), 26 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to CorMedix Inc. by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| SLDB Solid Biosciences Inc. | 5.47 | 0.4110 | -1230% | 22Weak | $586M |
| ANNX Annexon, Inc. | 3.60 | 0.7891 | -356% | 24Weak | $590M |
| PRME Prime Medicine, Inc. | 3.13 | - | - | 35Weak | $568M |
| PHAT Phathom Pharmaceuticals, Inc. | 7.40 | - | - | 41Weak | $599M |
| OLMA Olema Pharmaceuticals, Inc. | 6.87 | 0.4892 | -1304% | 24Weak | $601M |
| ZVRA Zevra Therapeutics, Inc. | 10.23 | 27.02 | +62% | 70Good | $607M |
| WVE Wave Life Sciences Ltd. | 3.09 | 1.35 | -128% | 30Weak | $609M |
| NVCT Nuvectis Pharma, Inc. | 18.93 | 1.18 | -1506% | 24Weak | $618M |
| CLYM Climb Bio, Inc. | 10.91 | 0.4867 | -2142% | 23Weak | $627M |
| VALN Valneva SE | 5.66 | - | - | 23No options | $537M |
| STTK Shattuck Labs, Inc. | 5.33 | 0.6164 | -765% | 30Weak | $535M |
| DRUG Bright Minds Biosciences Inc. | 54.21 | 8.34 | -550% | 32Weak | $535M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about CRMD
Is CRMD undervalued right now?
By the GLS models, yes: at 7.46 the stock is 91% below the average fair value of 83.15 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of CRMD and what does it mean?
CRMD scores 69 out of 100 (Good). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for CRMD?
83.15 per share as of 16 Oct 2026 - the simple average of the 7 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does CorMedix Inc. report earnings next?
The next earnings report is due on 11 Nov 2026 (before the open), 26 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does CRMD have listed options, and how liquid are they?
Yes. The nightly snapshot found 218 listed contracts with 33,735 open interest across all expiries and implied volatility of 88% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.